News | June 26, 2021
Shilpa Medicare receives DRDO approval for 2DG manufacturing
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
2DG has been given emergency approval by the Drug Controller General of India for COVID-19 patients in the country
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company has launched Perampil, at 2 mg (Rs. 49/strip of 7 tablets), 4 mg (Rs. 180/strip of 15 tablets) and 6 mg (Rs. 300/strip of 15 tablets) to improve patient access
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Emtricitabine and Tenofovir Disoproxil Fumarate tablets had estimated annual sales of US $2.1 billion in the U.S. according to IQVIA MAT March 2021
Glenmark has been granted a competitive generic therapy (CGT) designation for theophylline extended-release tablets
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Subscribe To Our Newsletter & Stay Updated
